Paul D Rennert (Paul Rennert)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Reduced Graphene Oxide

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Andreas A Hombach, Christine Ambrose, Roy Lobb, Paul D Rennert, Hinrich Abken
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2 + Solid Cancer. Cells 12 (2) (2023)
Andreas A Hombach, Christine Ambrose, Roy Lobb, Paul D Rennert, Hinrich Abken
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2 + Solid Cancer. Cells 12 (2) (2023)
Andreas A Hombach, Christine Ambrose, Roy Lobb, Paul D Rennert, Hinrich Abken
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2 + Solid Cancer. Cells 12 (2) (2023)
Andreas A Hombach, Christine Ambrose, Roy Lobb, Paul D Rennert, Hinrich Abken
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2 + Solid Cancer. Cells 12 (2) (2023)
Christine Ambrose, Lihe Su, Lan Wu, Fay J Dufort, Thomas Sanford, Alyssa Birt, Benjamin J Hackel, Andreas Hombach, Hinrich Abken, Roy R Lobb, Paul D Rennert
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells. PloS one 16 (3) (2021)
Paul D Rennert, Fay J Dufort, Lihe Su, Tom Sanford, Alyssa Birt, Lan Wu, Roy R Lobb, Christine Ambrose
Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo. Molecular cancer therapeutics 20 (10) (2021)